A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and COVID-19 mRNA vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 24 sites in 4 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 10th largest by enrollment, is one of 7 that started in 2024, is one of 15 in phase 3, and was the 10th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 7 started in 2024.
This study's enrollment of 841 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 17th largest by enrollment, is one of 6 that started in 2024, is one of 21 in phase 3, and was the 32nd registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to administration of the vaccines separately in adults aged 50 years and above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: In case of physical incapacity that would preclude the self-completion of the diary cards, either site staff can assist the participant (for activities performed during site visits) or the participant may assign a caregiver to assist him/her with this activity (for activities performed at home). However, at no time will the site staff or caregiver evaluate the participant's health status while answering diaries or make decisions on behalf of the participant.
A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.
Participants who have received previously a SARS-CoV-2 vaccine, being administered at least 3 months prior to study vaccination.
Female participants of childbearing potential may be enrolled in the study if the participant.
Exclusion Criteria:
Medical Conditions
Prior/Concomitant Therapy Use of any or non-registered product (drug, vaccine or invasive medical device) other than the study interventions during the period beginning 30 days before the first dose of study interventions and ending 30 days after the last vaccine administration, or their planned use during the study period.
Planned administration of a vaccine in the period starting 30 days before the first dose and ending 30 days after the last dose of study intervention(s) administration*, with the exception of inactivated and subunit influenza vaccines which can be administered up to 14 days before or from 14 days after the study vaccination.
*If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine, provided it is used according to the local governmental recommendations and Sponsor is notified.
Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the last blood sampling visit.
Up to 3 months prior to the study intervention administration:
Other Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of RSVPreF3 OA vaccine and a single dose of COVID-19 mRNA vaccine at Day 1, in different arms.
Biological: RSVPreF3 OA investigational vaccine · Biological: COVID-19 mRNA vaccine
Participants received a single dose of COVID-19 mRNA vaccine at Day 1, followed by a single dose of RSVPreF3 OA vaccine at Day 31.
Biological: RSVPreF3 OA investigational vaccine · Biological: COVID-19 mRNA vaccine
1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1 to participants in the Co-ad Group and on Day 31 to participants in the Control Group.
1 dose of COVID-19 mRNA vaccine is administered intramuscularly on Day 1 to participants in the Co-ad and Control Groups.
Adjusted Geometric Mean Titers (GMT) of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination
RSV-A neutralizing titers were provided as group GMTs and expressed as estimated dilution 60 (ED60) titers. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.
Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
Adjusted GMTs of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination
RSV-B neutralizing titers were provided as group GMTs and expressed as estimated dilution 60 (ED60) titers. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.
Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
Adjusted GMTs of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After the COVID-19 mRNA Vaccination
SARS-CoV-2 Omicron XBB.1.5 neutralizing titers against the pseudovirus bearing S protein were provided as group GMTs and expressed as titers. The neutralizing titer was calculated as the reciprocal serum dilution corresponding to the 50% signal reduction (NT50). Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.
Time frame: At 1 month post-COVID-19 mRNA vaccine dose administration (at Day 31 for both groups)
RSV-A Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination
Neutralizing titers for RSV-A were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.
Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
Mean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.
Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)
RSV-A Neutralizing Titers Expressed as Seroresponse Rate (SRR) at 1 Month After RSVPreF3 OA Vaccination
The SRR was defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) greater than or equal to (\>=) 4.
Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)
Percentage of Participants Having RSV-A Neutralizing Titers Greater or Equal to the Assay Cut-off Value at Pre-vaccination and at 1 Month After RSVPreF3 OA Vaccination
Percentage of participants with RSV-A neutralizing titers \>= to the assay cut-off value (i.e. lower limit of quantification \[LLOQ\]) are presented.
Time frame: At pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group) and at 1 month post-RSVPreF3 OA vaccine dose administration (Day 31 for Co-Ad Group and Day 61 for Control Group)
RSV-B Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination
Neutralizing titers for RSV-B were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.
Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
MGI of RSV-B Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.
Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)
RSV-B Neutralizing Titers Expressed as SRR at 1 Month After RSVPreF3 OA Vaccination
The SRR was defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) \>= 4.
Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)
Percentage of Participants Having RSV-B Neutralizing Titers Greater or Equal to Assay Cut-off Value at Pre-vaccination and at 1 Month After RSVPreF3 OA Vaccination
Percentage of participants with RSV-B neutralizing titers \>= to the assay cut-off value (i.e. LLOQ) are presented.
Time frame: At pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group) and at 1 month post-RSVPreF3 OA vaccine dose administration (Day 31 for Co-Ad Group and Day 61 for Control Group)
SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers Expressed as GMT at 1 Month After COVID-19 mRNA Vaccination
The SARS-CoV-2 Omicron XBB.1.5 neutralizing titers against the pseudovirus bearing S protein were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.
Time frame: At 1 month post-COVID-19 mRNA vaccine dose administration (Day 31 for both groups)
MGI of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After COVID-19 mRNA Vaccination
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.
Time frame: At 1 month post-COVID-19 mRNA vaccine dose administration (Day 31 for both groups) compared to pre-vaccination (at Day 1 for both groups)
Percentage of Participants Having SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers Greater Than or Equal to Assay Cut-off Value at Pre-vaccination and at 1 Month After COVID-19 mRNA Vaccination
Percentage of participants with SARS-CoV-2 Omicron XBB.1.5 neutralizing titers \>= to the assay cut-off value (i.e. LLOQ) are presented.
Time frame: At pre-vaccination (Day 1 for both groups) and at 1 month post-COVID-19 mRNA vaccine dose administration (Day 31 for both groups)
Number of Participants Reporting Each Solicited Administration Site Event, for Each Type of Vaccine Administered
The solicited administration site events after vaccination included pain, erythema/redness, and swelling. Any = occurrence of the events regardless of the intensity grade.
Time frame: Within 4 days (the day of administration and 3 subsequent days) after each type of vaccine (RSVPreF3 OA vaccine administered at Day 1 for Co-Ad Group and at Day 31 for Control Group, COVID-19 mRNA vaccine administered at Day 1 for both groups)
Number of Participants Reporting Each Solicited Systemic Event, for Each Day of Dose Administered
The solicited systemic events after vaccination included arthralgia, fatigue, fever (pyrexia), headache and myalgia. Fever was defined as body temperature equal or greater than 38 degrees Celsius (°C). Any = occurrence of the events regardless of the intensity grade.
Time frame: Within 4 days (the day of dose administered and 3 subsequent days) after each dose (administered at Day 1 for Co-Ad Group and at Days 1 and 31 for Control Group)
Number of Participants Reporting Unsolicited Adverse Events (AEs), for Each Day of Dose Administered
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study vaccine, which does not necessarily have a causal relationship with study vaccine. An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs must had been communicated by participant/participant's caregiver(s) who had signed the informed consent. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.
Time frame: Within 30 days (the day of vaccination and 29 subsequent days) after each dose (dose administered at Day 1 for Co-Ad Group and at Days 1 and 31 for Control Group)
Number of Participants Reporting Any Serious Adverse Events (SAEs)
An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.
Time frame: Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-Ad Group and Day 31 for Control Group])
Number of Participants Reporting Any Potential Immune-mediated Diseases (pIMDs)
The pIMD was defined as a subset of adverse events of special interest that included autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.
Time frame: Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-Ad Group and Day 31 for Control Group])
| Milestone | Co-Ad Group | Control Group |
|---|---|---|
| Started | 417 | 416 |
| Completed | 409 | 398 |
| Not completed | 8 | 18 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lost to follow-up | 6 | 9 |
| Withdrew: Withdrawal by subject | 1 | 7 |
| Withdrew: Other | 1 | 0 |
RSV-A neutralizing titers were provided as group GMTs and expressed as estimated dilution 60 (ED60) titers. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| Adjusted Geometric Mean Titers (GMT) of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination | 7885.8 (7168.1 to 8675.3) | 8803.4 (7985.0 to 9705.7) |
RSV-B neutralizing titers were provided as group GMTs and expressed as estimated dilution 60 (ED60) titers. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| Adjusted GMTs of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination | 7333.3 (6678.6 to 8052.0) | 7903.1 (7182.6 to 8695.9) |
SARS-CoV-2 Omicron XBB.1.5 neutralizing titers against the pseudovirus bearing S protein were provided as group GMTs and expressed as titers. The neutralizing titer was calculated as the reciprocal serum dilution corresponding to the 50% signal reduction (NT50). Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| Adjusted GMTs of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After the COVID-19 mRNA Vaccination | 1063.6 (960.2 to 1178.2) | 1392.0 (1256.9 to 1541.5) |
Neutralizing titers for RSV-A were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| RSV-A Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination | 8119.1 (7316.6 to 9009.7) | 8407.1 (7611.6 to 9285.8) |
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| Mean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination | 8.31 (7.46 to 9.26) | 10.21 (9.20 to 11.33) |
The SRR was defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) greater than or equal to (\>=) 4.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| RSV-A Neutralizing Titers Expressed as Seroresponse Rate (SRR) at 1 Month After RSVPreF3 OA Vaccination | 73.8 (69.1 to 78.2) | 81.3 (76.9 to 85.2) |
Percentage of participants with RSV-A neutralizing titers \>= to the assay cut-off value (i.e. lower limit of quantification \[LLOQ\]) are presented.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| At pre-vaccination | 100 (99.1 to 100) | 100 (99.1 to 100) |
| 1 month post RSVPreF3 administration | 100 (99.1 to 100) | 100 (99.0 to 100) |
Neutralizing titers for RSV-B were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| RSV-B Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination | 7537.1 (6791.4 to 8364.5) | 7588.9 (6896.0 to 8351.5) |
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| MGI of RSV-B Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination | 6.79 (6.08 to 7.59) | 8.19 (7.35 to 9.12) |
The SRR was defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) \>= 4.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| RSV-B Neutralizing Titers Expressed as SRR at 1 Month After RSVPreF3 OA Vaccination | 66.8 (61.8 to 71.5) | 75.5 (70.8 to 79.9) |
Percentage of participants with RSV-B neutralizing titers \>= to the assay cut-off value (i.e. LLOQ) are presented.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| At pre-vaccination | 100 (99.1 to 100) | 100 (99.1 to 100) |
| 1 month post RSVPreF3 administration | 100 (99.1 to 100) | 100 (99.0 to 100) |
The SARS-CoV-2 Omicron XBB.1.5 neutralizing titers against the pseudovirus bearing S protein were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers Expressed as GMT at 1 Month After COVID-19 mRNA Vaccination | 1030.4 (925.2 to 1147.6) | 1407.3 (1244.5 to 1591.4) |
The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| MGI of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After COVID-19 mRNA Vaccination | 4.25 (3.73 to 4.85) | 5.46 (4.74 to 6.30) |
Percentage of participants with SARS-CoV-2 Omicron XBB.1.5 neutralizing titers \>= to the assay cut-off value (i.e. LLOQ) are presented.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| At pre-dose administration | 95.1 (92.5 to 97.0) | 94.3 (91.6 to 96.4) |
| 1 month after COVID-19 mRNA vaccination | 99.7 (98.6 to 100) | 99.7 (98.6 to 100) |
The solicited administration site events after vaccination included pain, erythema/redness, and swelling. Any = occurrence of the events regardless of the intensity grade.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Erythema, within 4 days from COVID-19 mRNA Dosing | 19 | 20 |
| Erythema, within 4 days from RSVPreF3 OA Dosing | 34 | 26 |
| Pain, within 4 days from COVID-19 mRNA Dosing | 297 | 264 |
| Pain, within 4 days from RSVPreF3 OA Dosing | 302 | 235 |
| Swelling, within 4 days from COVID-19 mRNA Dosing | 10 | 13 |
| Swelling, within 4 days from RSVPreF3 OA Dosing | 20 | 9 |
The solicited systemic events after vaccination included arthralgia, fatigue, fever (pyrexia), headache and myalgia. Fever was defined as body temperature equal or greater than 38 degrees Celsius (°C). Any = occurrence of the events regardless of the intensity grade.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Arthralgia, within 4 days from dosing at Day 1 | 81 | 47 |
| Arthralgia, within 4 days from dosing at Day 31 | — | 36 |
| Fatigue, within 4 days from dosing at Day 1 | 166 | 115 |
| Fatigue, within 4 days from dosing at Day 31 | — | 95 |
| Fever, within 4 days from dosing at Day 1 | 26 | 7 |
| Fever, within 4 days from dosing at Day 31 | — | 9 |
| Headache, within 4 days from dosing at Day 1 | 120 | 98 |
| Headache, within 4 days from dosing at Day 31 | — | 83 |
| Myalgia, within 4 days from dosing at Day 1 | 170 | 117 |
| Myalgia, within 4 days from dosing at Day 31 | — | 91 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study vaccine, which does not necessarily have a causal relationship with study vaccine. An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs must had been communicated by participant/participant's caregiver(s) who had signed the informed consent. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Within 30 days after dosing at at Day 1 | 87 | 71 |
| Within 30 days after dosing at at Day 31 | — | 57 |
An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Number of Participants Reporting Any Serious Adverse Events (SAEs) | 16 | 14 |
The pIMD was defined as a subset of adverse events of special interest that included autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.
| Participants | Co-Ad Group | Control Group |
|---|---|---|
| Number of Participants Reporting Any Potential Immune-mediated Diseases (pIMDs) | 0 | 1 |
Collected over Solicited AEs were collected within 4 days post each vaccination. Unsolicited AEs were collected within 30 days post each vaccination. All cause mortality, SAEs and pIMDs were collected throughout the study period (from Day 1 up to 6 months post-last administration [last dose given at Day 1 for Co-ad Group and Day 31 for Control Group]).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Co-Ad Group | 0/417 (0%) | 16/417 (3.8%) | 365/417 (87.5%) |
| Control Group | 0/416 (0%) | 14/416 (3.4%) | 337/416 (81%) |
| Event | Co-Ad Group | Control Group |
|---|---|---|
| Atrial flutterCardiac disorders | 0/417 | 2/416 |
| Cardiac failureCardiac disorders | 2/417 | 0/416 |
| Atrial fibrillationCardiac disorders | 1/417 | 1/416 |
| Angina pectorisCardiac disorders | 0/417 | 1/416 |
| BradycardiaCardiac disorders | 0/417 | 1/416 |
| Cardiac arrestCardiac disorders | 0/417 | 1/416 |
| Cardiac failure congestiveCardiac disorders | 0/417 | 1/416 |
| PericarditisCardiac disorders | 0/417 | 1/416 |
| PneumoniaInfections and infestations | 1/417 | 1/416 |
| Device related infectionInfections and infestations | 0/417 | 1/416 |
| Event | Co-Ad Group | Control Group |
|---|---|---|
| Administration site painGeneral disorders | 336/417 | 303/416 |
| MyalgiaMusculoskeletal and connective tissue disorders | 170/417 | 158/416 |
| FatigueGeneral disorders | 166/417 | 154/416 |
| HeadacheNervous system disorders | 122/417 | 137/416 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 84/417 | 73/416 |
| Administration site erythemaGeneral disorders | 41/417 | 36/416 |
| PyrexiaGeneral disorders | 26/417 | 16/416 |
| Administration site swellingGeneral disorders | 25/417 | 19/416 |
| DiarrhoeaGastrointestinal disorders | 4/417 | 10/416 |
| NauseaGastrointestinal disorders | 6/417 | 7/416 |
Exposed set included all participants that received at least one study administration dose.
| Age, Continuous(YEARS) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Mean | 63.7 ± 8.4 | 63.5 ± 8.4 | 63.6 ± 8.4 |
| Sex: Female, Male(Participants) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Female | 216 | 223 | 439 |
| Male | 201 | 193 | 394 |
| Race/Ethnicity, Customized(Participants) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Other Races | 5 | 7 | 12 |
| White | 378 | 375 | 753 |
| Black or African American | 31 | 32 | 63 |
| Multiple | 1 | 1 | 2 |
| Not reported | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Apr 2024 to primary completion in Nov 2024, 6 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 6 months is below that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Arexvy · mRNA COVID-19 Vaccine
Respiratory Syncytial Virus Infections →